Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of ACHV is 14.3 and suggests 121% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre